METTL3/IGF2BP1 influences the development of non-small-cell lung cancer by mediating m6A methylation modification of TRPV1
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Methyltransferase 3 (METTL3) promotes non-small-cell lung cancer (NSCLC) by enhancing m6A modification of TRPV1. METTL3 and IGF2BP1 interaction upregulates TRPV1, driving NSCLC progression and M2 macrophage polarization.
Area Of Science
- Oncology
- Molecular Biology
- Epigenetics
Background
- Methyltransferase 3 (METTL3) is implicated in cancer progression, including non-small-cell lung cancer (NSCLC).
- Understanding the regulatory mechanisms of METTL3 in NSCLC is crucial for therapeutic development.
Purpose Of The Study
- To investigate the role and regulatory mechanisms of METTL3 in non-small-cell lung cancer (NSCLC).
- To elucidate the relationship between METTL3, IGF2BP1, and TRPV1 in NSCLC progression.
Main Methods
- Gene expression analysis (qRT-PCR, Western blot) and cell-based assays (MTT, colony formation, flow cytometry, Transwell) were employed.
- RNA immunoprecipitation and dual-luciferase reporter assays were used to determine molecular interactions.
- In vivo studies utilized a murine xenograft model to assess tumor growth.
Main Results
- TRPV1 expression was elevated in NSCLC, correlating with poor prognosis.
- METTL3 and IGF2BP1 epigenetically regulate TRPV1 expression via m6A modification.
- METTL3 deficiency suppressed NSCLC growth, metastasis, and M2 polarization, while TRPV1 overexpression rescued these effects.
Conclusions
- METTL3 interacts with IGF2BP1 to enhance m6A recognition of TRPV1 mRNA.
- This interaction promotes NSCLC cell growth and metastasis while inhibiting M2 macrophage polarization.
- METTL3 knockdown inhibits tumor growth in vivo by regulating TRPV1.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...